Search results
Results From The WOW.Com Content Network
Shares in Novartis were up 4.1 percent by 1540 GMT as investors welcomed the news. Alcon, a legacy from former Novartis boss Daniel Vasella's empire building, has been problematic since Novartis ...
On July 8, 2010, Alcon's independent director committee (IDC) had set up a $50 million litigation trust to ensure company's minority shareholders get the best deal from bidder Novartis AG. [15] On April 9, 2019, Alcon completed a 100% spin-off from Novartis. [4] [16] [17] The new standalone company is worth up to 28 billion Swiss francs. [18]
Alcon: At the time Novartis bought Alcon, they had annual sales of $6.5 billion and a net income of $2 billion. [128] In April 2019, Novartis completed the spin-off of Alcon as a separate commercial entity. [73] Sandoz: As of 2013, Sandoz has been recognized as the world's second-largest generic drug company.
The debut made Sandoz the largest new entrant to the Swiss stock exchange since 2019, when another Novartis spin-off, eyecare company Alcon, was valued at about 28 billion francs.
In September 2023, Novartis announced that the spin-off had been approved by its shareholders and that it would be completed by the next month, resulting in Novartis shareholders receiving one Sandoz share for every five Novartis shares. [42] [43] Sandoz was listed on the SIX Swiss Exchange with a market capitalization between $18 billion and ...
For premium support please call: 800-290-4726 more ways to reach us
Novartis' eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans ...
Stay informed and up-to-date with your local news, breaking news events, global events, savings events and in-depth coverage on a wide range of topics. From elections and technology to entertainment and human interest stories, we bring you the latest news from around the world.